Business Context and Reporting Period
Company: Bone Biologics Corp
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2015
Event: Entry into a Material Definitive Agreement (Item 1.01)
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a new contractual agreement.
Material Changes and Agreement Details
Effective November 13, 2015, the Company engaged Scott D. Boden, MD, as Chief Medical Advisor under an Independent Contractor Agreement.
- Compensation: Grant of a stock option to purchase 1,174,816 shares of common stock.
- Dilution Impact: Represents approximately 2.75% of fully diluted shares outstanding as of the Effective Date.
- Exercise Price: $1.58 per share, or the fair market value on the grant date if higher.
- Vesting Schedule: 10-year term with all shares vesting on the 4th anniversary of issuance.
- Acceleration Clauses:
- Termination: Pro-rated vesting applies if terminated without cause by the Company or by the Consultant.
- Change of Control: Full immediate vesting if a Change of Control occurs prior to termination.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary risk disclosed relates to potential dilution of existing shareholders due to the issuance of the stock option and the specific vesting conditions tied to termination or a Change of Control.
Investor Verification Checklist
- Verify the current fair market value of the stock to confirm the final exercise price ($1.58 vs. FMV).
- Review the Company's Equity Incentive Plan to confirm the availability of shares for this grant.
- Assess the impact of the 2.75% dilution on existing shareholder ownership.
- Confirm Dr. Boden's current roles at Emory University to evaluate potential conflicts of interest or resource allocation.